이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Chongqing Lummy Pharmaceutical 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rongzhao Qiu

최고 경영자

CN¥830.8k

총 보상

CEO 급여 비율	n/a
CEO 임기	4.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	5.3yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Feb 27

CEO

Rongzhao Qiu (30 yo)

4.2yrs

테뉴어

CN¥830,800

보상

Mr. Rongzhao Qiu is General Manager of Chongqing Lummy Pharmaceutical Co., Ltd. from June 12, 2020.

리더십 팀

이름	위치	테뉴어	보상	소유권
Rongzhao Qiu	General Manager	4.2yrs	CN¥830.80k	데이터 없음
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.4yrs	CN¥867.50k	데이터 없음
Wen Lai	Financial Director	8.4yrs	CN¥678.40k	데이터 없음
Song Lin	Deputy GM & Director	1.7yrs	CN¥410.20k	데이터 없음
Dan Cui	Deputy GM	6.4yrs	CN¥359.70k	0.0016% CN¥ 43.9k

5.3yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 300006 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.4yrs	CN¥867.50k	데이터 없음
Song Lin	Deputy GM & Director	1.6yrs	CN¥410.20k	데이터 없음
Yuan Yuan	Chairman of Supervisory Board	7.5yrs	데이터 없음	데이터 없음
Xujiang Chen	Independent Director	4.2yrs	CN¥88.50k	데이터 없음
Geng Chen	Independent Director	4.2yrs	CN¥88.50k	데이터 없음
Jiansheng Liang	Chairman	2.7yrs	CN¥729.40k	데이터 없음
Rihua Ou	Director	4.2yrs	데이터 없음	데이터 없음
Weiyan Tang	Director	4.2yrs	데이터 없음	데이터 없음
Changbi Li	Independent Director	4.2yrs	CN¥88.50k	데이터 없음
Huichuan Xu	Employee Supervisor	10.6yrs	데이터 없음	데이터 없음
Mingyue Tan	Supervisor	2.7yrs	데이터 없음	데이터 없음
Hai Run Wang	Director	1.6yrs	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 이사회: 300006 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

Chongqing Lummy Pharmaceutical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Less than half of directors are independent

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

Chongqing Lummy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.065 loss in FY 2022)

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.021 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.065 loss per share (vs CN¥0.10 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.021 loss per share (vs CN¥0.017 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

First quarter 2021 earnings released: EPS CN¥0.055 (vs CN¥0.01 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.40 loss per share (vs CN¥0.19 loss in FY 2019)

Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 200 million.

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥6.65

Hangzhou Bulaisen Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Sichuan Hezheng Pharmaceutical Co., Ltd. from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 170 million.

New 90-day low: CN¥7.08

New 90-day high: CN¥8.54

New 90-day high: CN¥8.21

Third quarter earnings released

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령